Rungsardthong Kanin, Mares-Sámano Sergio, Penny Jeffrey
University of Manchester, School of Pharmacy & Pharmaceutical Sciences, Stopford Building, M13 9PT, UK.
Bioinformation. 2012;8(19):907-11. doi: 10.6026/97320630008907. Epub 2012 Oct 1.
ABCC1 is a member of the ATP-binding Cassette super family of transporters, actively effluxes xenobiotics from cells. Clinically, ABCC1 expression is linked to cancer multidrug resistance. Substrate efflux is energised by ATP binding and hydrolysis at the nucleotide-binding domains (NBDs) and inhibition of these events may help combat drug resistance. The aim of this study is to identify potential inhibitors of ABCC1 through virtual screening of National Cancer Institute (NCI) compounds. A threedimensional model of ABCC1 NBD2 was generated using MODELLER whilst the X-ray crystal structure of ABCC1 NBD1 was retrieved from the Protein Data Bank. A pharmacophore hypothesis was generated based on flavonoids known to bind at the NBDs using PHASE, and used to screen the NCI database. GLIDE was employed in molecular docking studies for all hit compounds identified by pharmacophore screening. The best potential inhibitors were identified as compounds possessing predicted binding affinities greater than ATP. Approximately 5% (13/265) of the hit compounds possessed lower docking scores than ATP in ABCC1 NBD1 (NSC93033, NSC662377, NSC319661, NSC333748, NSC683893, NSC226639, NSC94231, NSC55979, NSC169121, NSC166574, NSC73380, NSC127738, NSC115534), whereas approximately 7% (7/104) of docked NCI compounds were predicted to possess lower docking scores than ATP in ABCC1 NBD2 (NSC91789, NSC529483, NSC211168, NSC318214, NSC116519, NSC372332, NSC526974). Analyses of docking orientations revealed P-loop residues of each NBD and the aromatic amino acids Trp653 (NBD1) and Tyr1302 (NBD2) were key in interacting with high-affinity compounds. On the basis of docked orientation and docking score the compounds identified may be potential inhibitors of ABCC1 and require further pharmacological analysis.
ABC - ATP-binding cassette, DHS - dehydrosilybin, MDR - multidrug resistance, NBD - nucleotide-binding domain, PDB - protein data bank.
ABCC1是ATP结合盒转运蛋白超家族的成员,可将外源性物质从细胞中主动外排。在临床上,ABCC1的表达与癌症多药耐药性相关。底物外排由核苷酸结合域(NBD)处的ATP结合和水解提供能量,抑制这些过程可能有助于对抗耐药性。本研究的目的是通过对美国国立癌症研究所(NCI)化合物进行虚拟筛选来鉴定ABCC1的潜在抑制剂。使用MODELLER生成ABCC1 NBD2的三维模型,同时从蛋白质数据库中检索ABCC1 NBD1的X射线晶体结构。基于已知在NBD处结合的黄酮类化合物,使用PHASE生成药效团假设,并用于筛选NCI数据库。对药效团筛选鉴定出的所有命中化合物进行分子对接研究时采用了GLIDE。最佳潜在抑制剂被鉴定为预测结合亲和力大于ATP的化合物。在ABCC1 NBD1中,约5%(13/265)的命中化合物对接分数低于ATP(NSC93033、NSC662377、NSC319661、NSC333748、NSC683893、NSC226639、NSC94231、NSC55979、NSC169121、NSC166574、NSC73380、NSC127738、NSC115534),而在ABCC1 NBD2中,约7%(7/104)对接的NCI化合物预测对接分数低于ATP(NSC91789、NSC529483、NSC211168、NSC318214、NSC116519、NSC372332、NSC526974)。对接方向分析表明,每个NBD的P环残基以及芳香族氨基酸Trp653(NBD1)和Tyr1302(NBD2)在与高亲和力化合物相互作用中起关键作用。基于对接方向和对接分数,鉴定出的化合物可能是ABCC1的潜在抑制剂,需要进一步的药理学分析。
ABC - ATP结合盒,DHS - 脱氢水飞蓟宾,MDR - 多药耐药性,NBD - 核苷酸结合域,PDB - 蛋白质数据库